| April 1 |
Hythiam Announces Results of Two Double-Blind, Placebo-Controlled Studies on Impact of PROMETA Treatment Program for Alcohol Dependence |
| April 1 |
Interleukin Genetics Presents Research Linking Vertebral Fractures to Gene Variations in Asian Women With Osteoporosis |
| April 1 |
Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder |
| April 2 |
Labopharm Reports Results for Phase III Study on Twice-daily Tramadol-acetaminophen Formulation |
| April 2 |
IDEA reports results from a prospective 3 years phase III study of Diractin (ketoprofen in Transfersome gel) |
| April 2 |
Biovista Inc. Announces Positive Efficacy Results in a Pre-Clinical Trial of its BVA-101 Repositioned Drug for Multiple Sclerosis |
| April 3 |
Phase III Study of Gilead's Darusentan for Resistant Hypertension Meets Primary Endpoints |
| April 3 |
New Study Demonstrates Improvements in LDL-Cholesterol on Top of Statin Therapy with HEP-40, a Novel Natural Product |
| April 6 |
Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder |
| April 6 |
Zosano Pharma, Inc. Presents Positive Phase 2 Results of Its Needle-Free Osteoporosis Therapy |
| April 7 |
Oncolytics Biotech Inc. Announces Positive Results of U.K. Phase II REOLYSIN and Radiation Combination Clinical Trial |
| April 7 |
Cerepro Phase III trial update |
| April 7 |
AngioChem to Present New ANG1005 Clinical Data at AACR |
| April 7 |
Phase I/II Trials of Anti-Androgen Drugs Show Promise for Patients with Advanced Prostate Cancer |
| April 8 |
Study Shows Single Dose of Reclast Prevents Postmenopausal Osteoporosis for at Least 2 Years |
| April 8 |
Kiadis Pharma Reports ATIR Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations |
| April 8 |
Medivation Announces Publication in Science Describing MDV3100's Novel and Potent Anti-Androgen Properties |
| April 8 |
The Journal of Cardiac Failure Publishes Results From Celladon Corporation's First-in-Human Phase 1/2 Clinical Trial in Advanced Heart Failure |
| April 8 |
bioXell S.p.A (CH) - BioXell reports top-line OAB Phase IIb results |
| April 8 |
Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Large Breast Cancer Tumors |
| April 8 |
ImQuest Presentation at Keystone Symposium Focuses on Advancements in Their Cancer Research and Development Program |
| April 8 |
Parkinson's Disease Medication Triggers Destructive Behaviors |
| April 9 |
OTHERA Announces Positive Interim Phase 2 Results of OT-551 Eye Drop Treatment for Dry AMD |
| April 9 |
New Clinical Data at ACC09 Show the CYPHER Sirolimus-eluting Coronary Stent Outperformed TAXUS LIBERTE and ENDEAVOR Stents in Key Outcome Measures |
| April 9 |
Data on AVEO Pharmaceuticals' AV-951 in Liver Cancer Model and Preclinical Activity in SCH 900105 (AV-299) to be Presented at AACR 100th Annual Meeting |
| April 9 |
Newly Published Phase III Study Shows Arzoxifene Significantly Increased Bone Mineral Density |
| April 10 |
ImmunoGen, Inc. Announces Presentations at the American Association for Cancer Research Annual Meeting |
| April 10 |
Curis Announces Presentations at American Association for Cancer Research Annual Meeting 2009 |
| April 10 |
Lancet Publication of Juvista (INN: Avotermin) Trial Results for the Improvement of Skin Scarring |
| April 10 |
Enzyme Therapy Slows Kidney Function Decline |
| April 13 |
Crofelemer, First-in-Class Anti-Diarrheal Agent, Positive Clinical Results to be Discussed at 13th Annual US-Japan CMSP in Kolkata, India |
| April 13 |
Preclinical Data on ARIAD's Oncology Pipeline to Be Presented at the AACR Annual Meeting |
| April 13 |
Phase III Data for Gilead Sciences' Darusentan Accepted as Late-Breaker Presentation at ASH 2009 |
| April 13 |
Ardea Biosciences Announces Investor and Analyst Event Participants and Webcast Information |
| April 13 |
New Approach to Progesterone Supplementation in ART Revealed in Recently Published White Paper |
| April 13 |
SuperGen to Highlight Oncology Pipeline Data in Multiple Presentations at the AACR Annual Meeting |
| April 14 |
Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial |
| April 14 |
Provenge Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study |
| April 14 |
Erectile Dysfunction Treatments Do Not Appear to Damage Vision Over Six Months |
| April 14 |
Acceleron Pharma Presents Preclinical Study Results for ACE-041 at the AACR 100th Annual Meeting 2009 |
| April 14 |
Genstruct to Present Results of Collaboration with Top Pharmaceutical Company at American Association for Cancer Research's Annual Meeting |
| April 14 |
Study Finds Discontinuation of Rosiglitazone Left Many Diabetes Patients Without Good Glycemic Control |
| April 14 |
Evotec AG (DE) - Evotec Reports Results of Phase II Proof-of-Concept Study with EVT 302 |
| April 14 |
Low Blood Sugar Events Increase Dementia Risk in Elderly Patients With Type 2 Diabetes, Kaiser Permanente Study Finds |
| April 14 |
Oncolytics Biotech Inc. Announces Positive Results of U.K. Phase II Reolysin and Radiation Combination Clinical Trial |
| April 15 |
AEterna Zentaris To Present Data on Anticancer Compounds AEZS-112 and AEZS-126 at AACR Annual Meeting |
| April 15 |
Pro-Pharmaceuticals' DAVANAT Prevents Mucositis, a Serious Side Effect of Chemotherapy, in All 100 Cancer Patients Treated |
| April 15 |
Angiotech Pharmaceuticals, Inc. - New study shows that Zilver PTX effectively treats blockages in critical thigh artery |
| April 15 |
Telik Announces Preclinical Presentations at AACR Annual Meeting |
| April 15 |
Lorus Announces Report of Evidence of Clinical Activity in Clinical Trial of LOR-2040 Combined With Capecitabine and Oxaliplatin in the Treatment of Advanced Metastatic Solid Tumors |
| April 15 |
Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Early Stage Breast Cancer Tumors |
| April 15 |
American Association for Cancer Research Hosts 100th Annual Meeting |
| April 15 |
Allos Therapeutics to Present at the American Association for Cancer Research Annual Meeting 2009 |
| April 15 |
Biogen Idec Showcases Leading Multiple Sclerosis Franchise and Pipeline at the 61st Annual Meeting of the American Academy of Neurology |
| April 15 |
Sirion Therapeutics Announces Positive Results From Interim Analysis of Phase II Trial and Receives FDA Fast Track Designation for Fenretinide |
| April 16 |
MedImmune Showcases Commitment to Cancer Research at Annual Meeting of the American Association for Cancer Research |
| April 16 |
Novagali Pharma completed a new Phase II with Cyclokat in dry eye |
| April 16 |
Cytopia Presentation on VDA CYT997 at AACR Conference |
| April 16 |
Alternative Therapy for Lupus Nephritis |
| April 17 |
Pharmacyclics Updates Positive Clinical Responses in its PCI-24781 Clinical Program Targeting HDAC |
| April 17 |
Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting |
| April 17 |
Promising interim results from Hybrigenics' Inecalcitol Phase II in Combination with Taxotere(R) for Hormone-Refractory Prostate Cancer |
| April 17 |
ERYtech Pharma Presents Very Encouraging Results of Its R&D Platform at the AACR in Denver |
| April 20 |
Peregrine Pharmaceuticals Reports Positive Preliminary Data From Phase II Bavituximab Lung Cancer Trial |
| April 20 |
Dendreon Announces Data on Provenge Potency and Long-Term Immune Responses in Androgen-Dependent Prostate Cancer |
| April 20 |
Lorus Therapeutics Presents New Findings for First-in-class Anticancer Drug Candidate LOR-253 |
| April 20 |
Pantec Biosolutions Reports Successful Phase I Study into the Delivery of Triptorelin Using P.L.E.A.S.E.R Technology |
| April 20 |
Poniard Announces Publication of Results of Picoplatin Phase 2 Study in Journal of Clinical Oncology |
| April 20 |
Mersana's Second Development Candidate, XMT-1107, Shows Superior Pharmacokinetics and Anti-Tumor Activity in Studies Presented at American Association of Cancer Research Meeting |
| April 20 |
Allos Therapeutics' Pralatrexate Demonstrates Anticancer Activity in Multiple Cancer Cell Lines |
| April 20 |
Array BioPharma's ARRY-614 Demonstrates Cytokine Inhibition and Anti-Tumor Activity in Preclinical Models of Hematological Cancers |
| April 20 |
Impax Pharmaceuticals Reports Positive Achievements on its Two Leading Brand Product Candidates IPX066 and IPX056 |
| April 20 |
Karmanos Cancer Institute Researchers Present Breast Cancer Advancements at Conference |
| April 21 |
Ardea Biosciences Announces Positive Results from a Phase 1 Study of Lead Hyperuricemia and Gout Candidate, RDEA594 and a Phase 2a Study of RDEA594's Prodrug, RDEA806 |
| April 21 |
Keryx Biopharmaceuticals Presents Encouraging Preclinical Data at Annual Meeting of the American Association of Cancer Research |
| April 21 |
AngioChem Presents New Positive Clinical Data on ANG1005 for Brain Cancers at AACR |
| April 21 |
New Pre-Clinical Data on RGB-286638 Multi-Targeted Kinase Inhibitor Presented at AACR |
| April 21 |
Array BioPharma's ARRY-543 Shows Potential Clinical Benefit in Cancer Patients |
| April 21 |
Ascenta Therapeutics Announces Results of Preclinical Evaluation of AT-406 in Multiple Cancer Models |
| April 21 |
Bioalliance Pharma Presents Results on Its New Biotherapy Plasmid AMEP for Metastatic Melanoma at the American Association for Cancer Research (AACR) 100Th Annual Meeting in Denver, April 18 to 22, 2009 |
| April 21 |
Seven Abstracts Featuring Exelixis Compounds to Be Presented at 2009 ASCO Annual Meeting |
| April 21 |
Isotechnika announces positive 12 month data from PROMISE trial |
| April 21 |
New study shows that re-treatment with Pegasys provides hep C patients with second chance for cure |
| April 21 |
NSLIJ Scientists to Present EKC-Cide Study Results at the GTC-Bio Conference on Ocular Diseases and Drug Discovery |
| April 21 |
Results Presented at AACR Differentiate STA-9090 in Hsp90 Inhibitor Class and Show Activity in Erlotinib (Tarceva)-resistant Lung Cancer Models |
| April 21 |
Karmanos Cancer Institute Researchers Study New Drug Combinations to Treat Childhood Leukemia |
| April 21 |
SuperGen Presents PIM kinase inhibitor SGI-1776 at American Association for Cancer Research Annual Meeting |
| April 21 |
Abstract on ˜Chemoablation of Metastatic Melanoma' Accepted for Joint Meeting of 7th World Congress on Melanoma and 5th Congress of the European Association of Dermato-Oncology |
| April 21 |
AVEO Announces Positive Finding for Triple VEGF Receptor Inhibitor AV-951 in Preclinical Model of Liver Cancer |
| April 21 |
Poniard Pharmaceuticals Presents Final Results of Phase 1 Study of Picoplatin in Patients with Metastatic Colorectal Cancer |
| April 21 |
International Stem Cell Reports Excellent Preliminary Results for Skin Rejuvenation |
| April 22 |
Clavis Pharma ASA (NO) - Promising Elacytarabine Clinical Results Presented at AACR |
| April 22 |
Phase III C-08 Study of Avastin in Early-Stage Colon Cancer Did Not Meet Primary Endpoint |
| April 22 |
Calistoga Pharmaceuticals Announces Presentations on CAL-101 and CAL-120 at the American Association for Cancer Research Annual Meeting |
| April 22 |
Vertex Pharmaceuticals to Present Data at EASL Suggesting Telaprevir's Potential for Use in a Broad Range of HCV Patients and Highlighting the Company's Expanded STAT-C Portfolio |
| April 22 |
Geron Presentations on Imetelstat (GRN163L) at the AACR 2009 Annual Meeting |
| April 22 |
Curis Presents CUDC-305 Preclinical Data at the AACR 100th Annual Meeting 2009 |
| April 22 |
Micromet Presents Data at AACR Meeting Showing Elimination of Colorectal Cancer Stem Cells by BiTE Antibody MT110 |
| April 22 |
Tranzyme Pharma Announces Positive Phase 2 Results with TZP-101 for Improvement of Symptoms in Patients with Gastroparesis |
| April 22 |
Lorus Therapeutics Announces Presentation of New Supportive Data for LOR-2040 in Acute Myeloid Leukemia |
| April 22 |
Celator Pharmaceuticals Presents New Data on CPX-351 And CPX-1 at the American Association for Cancer Research |
| April 22 |
Anergis SA Announces Successful Results of a Phase I/IIA Clinical Trial with Subcutaneous AllerT, its Novel Product for Desensitization of Patients Allergic to Birch Pollen |
| April 22 |
GTx Announces Toremifene 80 mg Phase III ADT Clinical Trial Data to be Presented at the Annual Meeting of the American Urological Association |
| April 22 |
Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells |
| April 22 |
NKTR-105 Demonstrates Superior Antitumor Activity and Improved Pharmacokinetics Over Docetaxel in Preclinical Studies Presented at AACR |
| April 22 |
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model |
| April 22 |
AEterna Zentaris Presents Phase 1 Results for AEZS-112 in Patients with Advanced Cancer and Lymphoma at AACR Annual Meeting in Denver |
| April 23 |
Pennsaid Phase 3 Study Results to be Published in Leading International PAIN Journal |
| April 23 |
Salix Presents Highly Statistically Significant Results from the Phase III Pivotal Study of Rifaximin for the Prevention and Maintenance of Remission of Hepatic Encephalopathy (HE) |
| April 24 |
Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication |
| April 24 |
Vical Reports Publication of Key Research Findings for Immunotherapeutic Herpes Vaccine |
| April 24 |
Valeant Pharmaceuticals Highlights Taribavirin Phase IIb 60-Week Data Presentation at European Association for the Study of Liver (EASL) Annual Meeting |
| April 24 |
ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients |
| April 24 |
Bristol-Myers Squibb and ZymoGenetics Present Positive 4-week Results of PEG-Interferon lambda with Ribavirin in Hepatitis C |
| April 24 |
InterMune Reports Presentation of Triple Combination Study of ITMN-191 at European Association for the Study of the Liver (EASL) |
| April 24 |
SCYNEXIS' SCY-635 Demonstrates Clinically Relevant Single-Agent Results in a Phase 1b Study in Adults with HCV |
| April 24 |
Argos Therapeutics Presents Research Validating Feasibility and Safety of its Arcelis™ Personalized Immunotherapy Platform for HIV |
| April 24 |
Medivir: New Phase IIa Data on TMC435 in Patients with Hepatitis C Presented at the Ongoing EASL - Meeting |
| April 24 |
Opexa Publication of Tovaxin Clinical Data in Journal of Clinical Immunology |
| April 24 |
Cannabis Compounds Reduce Multi-Drug Resistant Infections |
| April 24 |
Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients |
| April 24 |
New Publication of Landmark Study Demonstrates Gamunex Improves Health-Related Quality of Life in Patients with CIDP |
| April 24 |
Drug Therapy Reduces Neuroblastoma Tumor Growth in Pre-clinical Investigation |
| April 25 |
OctoPlus N.V. (NL) - OctoPlus' licensee Biolex presents Locteron Phase IIa results at EASL conference |
| April 25 |
GlobeImmune's Hepatitis C Therapeutic Vaccine, GI-5005, Improves EVR Rates to 94 percent in Phase 2 Clinical Trial |
| April 25 |
Roche Announces Collaboration to Investigate New Treatment Strategy With Tarceva in Lung Cancer |
| April 26 |
Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen |
| April 26 |
Telaprevir Data Presented at EASL Show Unprecedented SVR Rates in HCV Treatment-Failure Patients in PROVE 3 Study |
| April 26 |
Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C |
| April 26 |
Lancet Publishes Phase 3 Clinical Data on Basen® |
| April 27 |
Prostate Study Shows Botox May Be Safe, Effective Method for Managing Benign Prostatic Hyperplasia |
| April 27 |
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint |
| April 27 |
Phase II Results for GSK1838262 (XP13512) Reported for Neuropathic Pain Associated with Diabetic Peripheral Neuropathy |
| April 27 |
Juvaris BioTherapeutics' Vaccine Adjuvant, JVRS-100, Generates Superior T-Cell Mediated Immune Responses to Influenza in Clinical Trial |
| April 27 |
Dynavax Presents Additional Phase 3 Data for HEPLISAV Hepatitis B Vaccine at EASL Medical Conference |
| April 27 |
Sepracor Reports Preliminary Phase III Study Results for OMNARIS HFA Nasal Aerosol in Seasonal Allergic Rhinitis |
| April 27 |
Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial |
| April 27 |
Curis Presents Preclinical Data for CU-903 at Keystone Symposia Event “PI3 Kinase Signaling in Disease” |
| April 27 |
Avila Presents Preclinical Data on a Novel, Orally-Available, Protease Inhibitor, AVL181, for Hepatitis C Infection at EASL 2009 Meeting |
| April 27 |
VaxInnate's Seasonal Flu Vaccine Candidate Shown Safe and Immunogenic in Phase I Study |
| April 27 |
First Ever Prospective Fracture Study in Prostate Cancer Patients on ADT Reveals These Men Are at High Risk for Skeletal Fractures |
| April 27 |
Dynavax Presents Additional Phase 3 Data for Heplisav Hepatitis B Vaccine at EASL Medical Conference |
| April 27 |
New Data Presented at AUA's Annual Conference Prove GELNIQUE (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients |
| April 27 |
Tadalafil May Effectively Treat Symptoms of BPH-LUTS in Addition to Erectile Dysfunction |
| April 27 |
CEL-SCI Presents Data at Prestigious Medical Conference Demonstrating That Its L.E.A.P.S. Technology Stimulates Maturation of Human Blood Cells Into Dendritic Cells Suggesting Potential for Prevention and Treatment of Infectious Disease |
| April 27 |
Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting |
| April 27 |
Theratechnologies presents additional data from studies evaluating tesamorelin at the Annual Canadian Conference on HIV/AIDS Research |
| April 28 |
Ocera Therapeutics Presents Data on AST-120 in Patients With Hepatic Encephalopathy at the European Association for the Study of Liver Disease Annual Meeting |
| April 28 |
Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies |
| April 28 |
Clinical Update - Debio 025 in Hepatitis C |
| April 28 |
PharmAthene Presents Data for SparVax, a Novel Vaccine for the Prevention and Treatment of Anthrax Infection, at the 12th Annual Conference on Vaccine Research |
| April 28 |
Presented Data Confirm That Rapaflo (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients |
| April 28 |
Data Presented at AUA Demonstrate Provenge Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study |
| April 28 |
Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia |
| April 28 |
Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients |
| April 28 |
Data Show Dutasteride Reduces Prostate Cancer Diagnosis in Men With Increased Risk |
| April 28 |
Testosterone Undecanoate Achieves and Maintains Normal Testosterone Levels in Hypogonadal Men With Five Injections Per Year, New Data Show |
| April 28 |
Cempra Pharmaceuticals Inc. Announces Lead Macrolide is Active in vitro Against Clinically Significant Antibiotic-Resistant Pathogenic Organisms |
| April 29 |
Active Biotech (SE) - Active Biotech presents S100A9 as a target for quinoline compounds |
| April 29 |
Excellent Phase III results of Biofrontera's BF-200 ALA presented at dermatology congress |
| April 29 |
Isotechnika announces Phase 3 ESSENCE data meets primary endpoint in psoriasis |
| April 29 |
New data presented at American Academy of Neurology congress show 80-83% of MS patients on oral FTY720 were relapse-free for one year |
| April 29 |
MRI Data Showing Tysabri Promoted Remyelination Presented at the 61st Annual Meeting of the American Academy of Neurology |
| April 29 |
Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet |
| April 29 |
Genta Updates Late-Stage Progress of its Phase 3 Trial of Genasense in Advanced Melanoma |
| April 29 |
New England Journal of Medicine Publishes Landmark Clinical Studies of the Investigational Hepatitis C Virus Protease Inhibitor Telaprevir |
| April 29 |
Lyrica Significantly Reduced Pain and Improved Other Symptoms of Post-Traumatic Peripheral Nerve Pain, New Data Show |
| April 29 |
New Treatment Discovered for Restless Legs Syndrome Improves Sleep |
| April 29 |
Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer |
| April 29 |
Addex Pharmaceuticals (CH) - Addex Presents Data on ADX10059 at the Annual Meeting of the American Academy of Neurology |
| April 29 |
Advaxis' Phase 1 Clinical Cervix Cancer Study Accepted for Publication in Leading Peer-Reviewed Science Journal Vaccine |
| April 29 |
New Analyses from 16-Year Follow-up Trial with Betaseron Demonstrated that Early and Sustained Treatment of Multiple Sclerosis Patients Enrolled in the Trial Affected Their Long-term Outcomes |
| April 29 |
Long-Term Study with Copaxone Indicated Protective Effect on Brain Tissue in Multiple Sclerosis Patients |
| April 30 |
Phase 3 Data on VIVUS' Qnexa to Be Presented at 17th European Congress on Obesity |
| April 30 |
Novartis International AG (CH) - Novartis investigational adjuvanted (MF59) pre-pandemic avian influenza vaccine Aflunov shows long lasting, broadly cross-protective immune response |
| April 30 |
UCB (BE) - UCB announces first results from Phase III brivaracetam studies in epilepsy |
| April 30 |
Two-Year Phase III Data Presented at AAN 61st Annual Meeting Show Positive Outcome of Cladribine Tablets in Patients with Multiple Sclerosis |
| April 30 |
LifeCycle Pharma Announces Positive Interim Results of Phase 2 Clinical Trial of LCP-Tacro for the Prevention of Organ Rejection in De Novo Kidney Transplant Patients |
| April 30 |
A Phase IIb Study Testing the Combination of Methotrexate and CF101 in Rheumatoid Arthritis Patients Failed to Achieve Primary Efficacy Endpoint |
| April 30 |
Agios Pharmaceuticals Highlights Extensive Cancer Metabolism Research at AACR |
| April 30 |
Sciele Pharma and Plethora Solutions Announce That PSD502 Demonstrates Substantial Benefit in the Treatment of Premature Ejaculation |
| April 30 |
Provectus Abstract Titled “Chemoablation of Melanoma with Intralesional Rose Bengal (PV-10)" to be Presented at ASCO Scientific Program on June 1 in Orlando |
| April 30 |
Dynavax Presents Data From Novel Universal Flu Vaccine Candidate |
| April 30 |
Solifenacin Shows Superior Tolerability Compared to Oxybutynin Immediate-Release |
| April 30 |
Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis |
| April 30 |
Quigley Pharma Announces Drug Study That May Reverse Diabetic Peripheral Neuropathy |
| April 30 |
First Ten-Year Follow-Up Shows That Treatment with AVONEX Leads to Long-Term Benefits in Early Multiple Sclerosis Patients |
